What Over-the-counter Drugs Are Used to Treat Vulvovaginal Candidiases?
Content Sponsored by SCYNEXIS, Inc., an ACNM Aureate Industry Partner
Equally trusted women's wellness care providers, Certified Nurse Midwives (CNMs) and Certified Midwives (CMs) provide a range of holistic care to women during pregnancy and the postpartum menstruum; still, many CNM/CMs besides provide care to women throughout their lifespan. Indeed, because of the trust, rapport and relationships that develop during pregnancy and birth, some women choose a midwife every bit their main intendance provider.
One status that impacts approximately 75% of women during their lifetime and that CNM/CMs are well versed in diagnosing and treating is Vulvovaginal Candidiasis (VVC).iOf the 10 million office visits to women'south health care providers for vaginal and vulvar symptoms, VVC infections account for approximately 20-25%.two In addition, upwardly to 45% of women will have recurrent VVC, which is defined equally >4 infections per year, while 30% will have 6 to20 episodes in their lifetime.3 During pregnancy, approximately 10% of women develop VVC.
Though 85-95% of cases of VVC are acquired byCandida albicans, the remaining five to 15% of infections are acquired by non-albicans Candida (NAC). As more providers encounter women with resistant or persistent symptoms, the use of cultures and Nucleic Acrid Distension Testing (NAAT) for more than accurate diagnosis has revealed many otherCandida species that are causative, includingC. glabrata, C. krusei, C. parapsilosis, andC. tropicalis. 4 – half dozen Women with recurrent VVC are twice as probable to have a NAC species.7
Despite the profound touch that both acute and recurrent VVC may have on a woman'southward physical and psychological well-existence, many clinicians dismiss VVC as "simply a yeast infection." Even so, VVC may bear upon several aspects of a woman'south well-being simultaneously, ranging from changes in self-esteem, personal embarrassment, and reduced conviction, to fears of being stigmatized not only by partners, but too past providers. In addition, many women experience an suspension in their sexual function and satisfaction. It's also of import to annotation that for women with recurrent VVC, there is the added brunt of multiple office visits, with a concomitant disruption in their productivity.8-11
Until recently, there has only been ane class of handling, azoles, available to treat VVC. Though ubiquitous, many clinicians are not aware that azoles are fungistatic and not fungicidal (pregnant the amanuensis does not "kill" the offending pathogen). The azole course of medications includes over the counter and prescription vaginal creams comprising butoconazole, clotrimazole, miconazole and terconazole. In addition, a prescription oral grooming, fluconazole, is bachelor and is about frequently prescribed every bit women and providers adopt an oral treatment. Unfortunately, fluconazole is non effective in over 30% of women, does non have broad spectrum activeness against NAC and there has been increasing antifungal resistance reported over the last twenty years.12
With recurrent VVC, many women and their providers are frustrated by the lack of efficacy with the electric current azole treatments and often resort to using boric acid suppositories with varying degrees of success.
Clinicians have lived with a gap in treatment options for decades. Recently, the FDA approved a new medication to care for VVC, BREXAFEMME® (ibrexafungerp tablets). BREXAFEMME is a fungicidal triterpenoid with a novel machinery of activity that works to suspension down the fungal cell wall, killing the jail cell. This is different from azoles, which are fungistatic. Unlike oral fluconazole, which delivers a vaginal tissue to plasma ratio of ane:1, the concentration of BREXAFEMME in the vaginal tissue is 9 times greater than the levels in the serum, and information technology besides maintains activity in a low pH environment ofttimes encountered in the vagina.
In the two phase 3 clinical trials, a clinical cure was defined every bit a complete resolution of signs and symptoms at mean solar day x and complete resolution of symptoms at day 25. At both time points, there was a statistically significantly greater percentage of women who had a clinical cure on BREXAFEMME than on placebo. BREXAFEMME also demonstrated a sustained efficacy at mean solar day 25 with a greater number of women having complete resolution of symptoms. Women took the 1-twenty-four hours treatment, which consists of 2-150 mg tablets taken twice daily, for a total dosage of 600 mg.. The majority of adverse events included diarrhea, nausea and intestinal pain, however none of the participants dropped out of the trial due to these adverse events.
Every bit clinicians, we take long recognized the gap in our ability to treat VVC and help our patients return to their lives. We at present have a novel 1-twenty-four hour period oral handling that is fungicidal and highly efficacious for our patients with VVC.
1 Azie Due north, et al. Proficient Opin Investig Drugs . 2020;29(9):893-900. 2. Anderson MR. JAMA . 2004;291(11):1368-1379. 3. Johnson et al. J Depression Genit Tract Dis . 2010;14(iv):287-294. four. Sobel JD. Lancet . 2007;369(9577):1961-1971. v . Sobel JD. Am J Obstet Gynecol . 2016;214(i):15-21. 6 . Willems HME, et al. J Fungi (Basel) . 2020;half dozen(i):27. doi:10.3390/jof6010027 . 7 . Achkar JM, Fries BC. Clin Microbiol Rev . 2010;23(2):253-273 8. Fukazawa EI, et al. Arch Gynecol Obstet. 2019;300(3):647-650. 9. Denning DW, et al. Lancet Infect Dis. 2018;xviii(11):e339-e347. doi:10.1016/S1473-3099(xviii)30103-viii. ten. Adolfsson A, et al. Adv Sexual Med. 2017;vii:1-19. doi : x.4236/asm.2017.71001. 11. Moshfeghy Z, et al. J Turk Ger Gynecol Assoc . 2020;21(2):90-96 . 12. B ulik , C.C., Sobel, J.D. and Nailor , Thou.D. (2011), Susceptibility profile of vaginal isolates of Candida albicans prior to and following fluconazole introduction – bear upon of two decades. Mycoses, 54: 34-38.
Source: https://quickening.midwife.org/roundtable/an-update-on-the-treatment-of-vulvovaginal-candidiasis/
0 Response to "What Over-the-counter Drugs Are Used to Treat Vulvovaginal Candidiases?"
Post a Comment